Hoylu AB: NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF HOYLU AB (PUBL) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update
> Several major clinical milestones achieved in 2020 by AsiDNA, including promising initial results in combination with chemotherapy and the launch of a new study to evaluate the abrogation of resistance to a targeted therapy
> Cash position of €14.5 million at December 31, 2020 supplemented by €14.7 million in new financing obtained in early 2021
> Extended financial visibility through the end of 2022, enabling the expansion of clinical and industrial development of AsiDNA
Regulatory News:
https://us02web.zoom.us/webinar/register/WN T6v8Hc8TRU67rKXPrz2nXw
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO) (Paris:ALONX) (NASDAQ OMX:ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today reported its consolidated financial results for the fiscal ending December 31,
NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF HOYLU AB (PUBL)
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the Annual General Meeting in Hoylu AB (publ), and in case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF HOYLU AB (PUBL)
The shareholders of Hoylu AB (publ), reg. no 559084-6381 (the “
Company”) are hereby summoned to attend the annual general meeting held at 09:00 (CEST) on Friday May 21, 2021 at the premises of Eversheds Sutherland Advokatbyrå located at Strandvägen 1, Stockholm, Sweden. Registration begins at 08.45 (CEST).
Nasdaq Stockholm AB: The observation status for ArcAroma AB is updated (173/21)
On January 20, 2021, the shares in ArcAroma AB ( ArcAroma ) were given
observation status with reference to an adopted merger plan between ArcAroma
and OptiFreeze AB ( Optifreeze ), according to which ArcAroma will be absorbed
by OptiFreeze.
Today, April 20, 2021, ArcAroma applied for delisting of its shares from Nasdaq
First North Growth Market.
The rules of Nasdaq First North Growth Market state that an issuer may be given
observation status if the issuer has applied to have its financial instruments
removed from Nasdaq First North Growth Market.
With reference to the above, Nasdaq Stockholm AB decides to update the
– LIDDS publishes Annual Report for 2020
The Annual Report is attached to this press release and alos available on LIDDS website: https://liddspharma.com/investors/#financial-reports.
For more information, please contact:
Monica Wallter, CEO, LIDDS +46 (0)737 07 09 22 [email protected]
LIDDS AB is required to disclose this information pursuant to
Nasdaq First North Growth Market – Rulebook
. The information was submitted for publication, through the agency of the aforementioned contact person, on April 16, 2021 at 15:00 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical ph